← Ablatotech Vitals
Pediatrics EvidenceDigest

Evidence-based management of pediatric acute severe hyperkalemia in emergency and inpatient settings

Pediatrics · EvidenceDigest

Reviewed by the Ablatotech Vitals editorial team
November 19, 2026 · Reviewer: Vitals Editorial Team
Educational use only. This digest is AI-curated commentary reviewed by clinicians. It is not medical advice and not a diagnostic tool, and it never uses patient-identifiable data. Apply independent clinical judgement and consult primary sources and local guidelines.

Acute severe hyperkalemia in pediatric patients is a potentially life-threatening electrolyte disturbance requiring prompt recognition and management in emergency and inpatient settings. Current evidence supports a stepwise approach combining rapid cardiac membrane stabilization, potassium redistribution, and potassium elimination strategies. Intravenous calcium administration remains the cornerstone for immediate cardioprotection, while insulin with glucose and beta-2 agonists facilitate intracellular potassium shift. Definitive potassium removal through diuretics, cation exchange resins, or dialysis should be considered based on severity and underlying etiology. Despite advances, pediatric-specific protocols remain limited, and management often extrapolates from adult data and expert consensus. Clinicians should tailor interventions to individual patient risk, monitor for treatment complications, and engage multidisciplinary teams early.

Clinical bottom line

Acute severe hyperkalemia in pediatric patients is a potentially life-threatening electrolyte disturbance requiring prompt recognition and management in emergency and inpatient settings. Current evidence supports a stepwise approach combining rapid cardiac membrane stabilization, potassium redistribution, and potassium elimination strategies. Intravenous calcium administration remains the cornerstone for immediate cardioprotection, while insulin with glucose and beta-2 agonists facilitate intracellular potassium shift. Definitive potassium removal through diuretics, cation exchange resins, or dialysis should be considered based on severity and underlying etiology. Despite advances, pediatric-specific protocols remain limited, and management often extrapolates from adult data and expert consensus. Clinicians should tailor interventions to individual patient risk, monitor for treatment complications, and engage multidisciplinary teams early.

What the evidence shows

Acute hyperkalemia, defined variably but often as serum potassium >6.0 mmol/L, can precipitate fatal cardiac arrhythmias in children. Lemoine et al. (2021) provide a comprehensive narrative review emphasizing the urgency of electrocardiogram (ECG) monitoring and immediate interventions to stabilize myocardial excitability. Intravenous calcium gluconate or calcium chloride is recommended as first-line therapy to antagonize the membrane effects of hyperkalemia, with onset within minutes and duration of 30–60 minutes (Lemoine et al., 2021).

Following stabilization, shifting potassium intracellularly is critical. Insulin administered with glucose promotes cellular uptake of potassium, with effects typically observed within 15–30 minutes. Beta-2 adrenergic agonists, such as nebulized albuterol, can augment this effect but may cause tachycardia and are less predictable in younger children (Lemoine et al., 2021). Sodium bicarbonate use remains controversial and is generally reserved for cases with concomitant metabolic acidosis.

For potassium elimination, loop diuretics and cation exchange resins (e.g., sodium polystyrene sulfonate) have been traditionally used, although evidence for efficacy and safety in pediatrics is limited. Dialysis remains the definitive treatment for refractory or severe hyperkalemia, especially in the context of renal failure or toxin ingestion (Lemoine et al., 2021; Advanced Emergency Nursing Journal, 2024).

The Advanced Emergency Nursing Journal (2024) highlights the importance of continuous cardiac monitoring and frequent serum potassium reassessment during treatment. Pediatric-specific dosing and protocols are less well established, necessitating individualized care plans and specialist consultation.

Caveats and uncertainty

Most evidence guiding pediatric hyperkalemia management is extrapolated from adult studies or based on expert consensus due to the rarity and heterogeneity of severe pediatric cases. Randomized controlled trials specifically in children are lacking, limiting high-quality evidence for optimal dosing, timing, and combination of therapies.

The safety profile of cation exchange resins in children is uncertain, with concerns about gastrointestinal adverse effects. Beta-2 agonists may be less effective or poorly tolerated in younger pediatric populations. The role of sodium bicarbonate remains debated, with potential risks of volume overload and alkalosis.

Additionally, underlying causes such as acute kidney injury, hemolysis, or medication effects require targeted management, which may complicate standard hyperkalemia protocols. The timing and indications for dialysis in pediatric hyperkalemia are not standardized and depend on institutional resources and patient factors.

How this may change practice

This evidence digest underscores the critical need for rapid recognition and a structured, evidence-informed approach to pediatric acute severe hyperkalemia in emergency and inpatient settings. Clinicians should prioritize early ECG monitoring and calcium administration for cardioprotection, followed by potassium redistribution therapies tailored to the child’s age and clinical status.

Institutions may consider developing pediatric-specific hyperkalemia protocols incorporating current evidence and expert recommendations to standardize care and reduce delays. Multidisciplinary collaboration with nephrology, critical care, and pharmacy is essential for complex cases, especially when dialysis or advanced therapies are indicated.

Ongoing education regarding the limitations and risks of available treatments, including cation exchange resins and beta-2 agonists, is important to optimize safety. Future research should focus on pediatric-specific pharmacokinetics, efficacy, and safety of hyperkalemia treatments to refine guidelines and improve outcomes.


References

  1. Lemoine Loic, et al. An Evidence-Based Narrative Review of the Emergency Department Management of Acute Hyperkalemia. The Journal of Emergency Medicine 2021;61:385-394. DOI:10.1016/j.jemermed.2020.11.028
  2. Anonymous, et al. Acute Hyperkalemia Management in the Emergency Department. Advanced Emergency Nursing Journal. 2024.
  3. Lam Adele, et al. Pediatric Hospital Medicine: Textbook of Inpatient Management. Pediatric Emergency Care 2004;20:345-352. DOI:10.1097/01.pec.0000106247.50288.6d

© 2026 Ablatotech, Inc. All rights reserved. Reviewed by the Ablatotech Vitals editorial team